Novartis phase III trial shows Afinitor delays tumour growth in HER2 positive ... pharmabiz.com Novartis has presented results from a pivotal phase III trial of a treatment regimen including Afinitor (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior ... Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor ... Novartis reports positive breast cancer data for Afinitor NOVARTIS AG : pivotal Phase III trial shows Afinitor® significantly delays ... |
